跳转至内容
Merck
CN
所有图片(2)

文件

安全信息

MKI1MAG-94K

Millipore

MILLIPLEX®小鼠肾损伤磁珠组套1 - 毒性多重检测试剂盒

The analytes available for this multiplex kit are: β-2-Microglobulin, IP-10, KIM-1, Renin, TIMP-1, VEGF (for urine samples) or IP-10, KIM-1, Renin, and TIMP-1 (for serum/plasma samples).

登录查看公司和协议定价
所有图片(2)
UNSPSC代码:
12161503
eCl@ss:
32161000
NACRES:
NA.84

质量水平

200

种属反应性

mouse

制造商/商品名称

Milliplex®

assay range

accuracy: 73-98%
sensitivity: 0.001-0.041 ng/mL
(MinDC+2SD)
standard curve range: 0.001-1 ng/mL
(VEGF)
standard curve range: 0.005-5 ng/mL
(IP-10)
standard curve range: 0.01-15 ng/mL
(KIM-1)
standard curve range: 0.02-25 ng/mL
(TIMP-1)
standard curve range: 0.05-50 ng/mL
(β-2-Microglobulin)
standard curve range: 0.05-50 ng/mL
(Renin)

技术

multiplexing: suitable

检测方法

fluorometric (Luminex xMAP)

运输

wet ice

相关类别

一般描述

MILLIPLEX®小鼠肾损伤珠组套1包含使用Luminex® xMAP®技术以任何组合测量以下六个生物标志物所需的所有组件: β-2-微球蛋白、IP-10、KIM-1、肾素、TIMP-1、VEGF。该试剂盒使用96孔格式，包含冻干标准混合物，两个对照品，可以一式两份测量多达38份尿液样品。

应用

  • 分析物：β-2-微球蛋白、IP-10、KIM-1、肾素TIMP-1、VEGF
  • 建议样品类型：尿液
  • 建议样品稀释度：1:25
  • 测定运行时间：过夜
  • 研究类别：毒性

特点和优势

通过在此组套中选择可用的分析物来设计多重试剂盒。

其他说明

灵敏度：请参阅试剂盒方案了解单个检测试剂盒的灵敏度。
请联系技术服务部了解稀释线性。

法律信息

Luminex is a registered trademark of Luminex Corp
MILLIPLEX is a registered trademark of Merck KGaA, Darmstadt, Germany
xMAP is a registered trademark of Luminex Corp

警示用语：

Danger

危险分类

Acute Tox. 3 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Aquatic Chronic 2 - Eye Dam. 1 - Skin Sens. 1 - STOT RE 2

靶器官

Respiratory Tract

WGK

WGK 3

法规信息

新产品

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ （Lot或Batch）字后找到。

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Lucía Echevarría et al.
Methods in molecular biology (Clifton, N.J.), 2434, 371-384 (2022-02-26)
Antisense oligonucleotides (ASO) therapeutics hold great promise for the treatment of numerous diseases, and several ASO drugs have now reached market approval, confirming the potential of this approach. However, some candidates have also failed, due to limited biodistribution/uptake and poor
Karima Relizani et al.
Molecular therapy. Nucleic acids, 8, 144-157 (2017-09-18)
Antisense oligonucleotides (AONs) hold promise for therapeutic splice-switching correction in many genetic diseases. However, despite advances in AON chemistry and design, systemic use of AONs is limited due to poor tissue uptake and sufficient therapeutic efficacy is still difficult to
Karima Relizani et al.
Nucleic acids research, 50(1), 17-34 (2021-12-12)
Tricyclo-DNA (tcDNA) is a conformationally constrained oligonucleotide analog that has demonstrated great therapeutic potential as antisense oligonucleotide (ASO) for several diseases. Like most ASOs in clinical development, tcDNA were modified with phosphorothioate (PS) backbone for therapeutic purposes in order to
Gene Ryan Crislip et al.
Biomolecules, 12(2) (2022-02-26)
BMAL1 is a core mammalian circadian clock transcription factor responsible for the regulation of the expression of thousands of genes. Previously, male skeletal-muscle-specific BMAL1-inducible-knockout (iMS-BMAL1 KO) mice have been described as a model that exhibits an aging-like phenotype with an
Monica Javidnia et al.
Journal of Alzheimer's disease : JAD, 60(2), 461-481 (2017-09-05)
Hyperphosphorylation and aggregation of tau protein is a critical factor in many neurodegenerative diseases. These diseases are increasing in prevalence, and there are currently no cures. Previous work from our group and others has shown that tyrosine kinase inhibitors (TKIs)
查看所有相关文献

相关内容

Kidney Toxicity Multiplex Assays | MILLIPLEX®

Multiplex kidney toxicity assays detect nephrotoxicity biomarkers in small samples, minimizing time and costs for toxicity screening.

Multiplex Toxicity Assays

MILLIPLEX® toxicity assays advance liver, kidney, and genotoxicity research by simultaneously measuring multiple toxicity biomarkers.

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门